These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18663482)

  • 1. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
    La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
    Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
    Ripamonti CI; Maniezzo M; Campa T; Fagnoni E; Brunelli C; Saibene G; Bareggi C; Ascani L; Cislaghi E
    Ann Oncol; 2009 Jan; 20(1):137-45. PubMed ID: 18647964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T; Cheng A; Stein B; Goss A
    J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
    Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G
    J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
    J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Gabbert TI; Hoffmeister B; Felsenberg D
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.
    Aguiar Bujanda D; Bohn Sarmiento U; Cabrera Suárez MA; Aguiar Morales J
    Ann Oncol; 2007 Mar; 18(3):556-60. PubMed ID: 17082512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
    Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
    Dimopoulos MA; Kastritis E; Bamia C; Melakopoulos I; Gika D; Roussou M; Migkou M; Eleftherakis-Papaiakovou E; Christoulas D; Terpos E; Bamias A
    Ann Oncol; 2009 Jan; 20(1):117-20. PubMed ID: 18689864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
    Rathbone EJ; Brown JE; Marshall HC; Collinson M; Liversedge V; Murden GA; Cameron D; Bell R; Spensley S; Agrawal R; Jyothirmayi R; Chakraborti P; Yuille F; Coleman RE
    J Clin Oncol; 2013 Jul; 31(21):2685-91. PubMed ID: 23796998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
    Haidar A; Jønler M; Folkmar TB; Lund L
    Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.
    Carmagnola D; Celestino S; Abati S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
    Wessel JH; Dodson TB; Zavras AI
    J Oral Maxillofac Surg; 2008 Apr; 66(4):625-31. PubMed ID: 18355585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
    Hoefert S; Schmitz I; Tannapfel A; Eufinger H
    Clin Oral Investig; 2010 Jun; 14(3):271-84. PubMed ID: 19536569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.